Lessons From a Lifelong Patient Turned Oncologist Eric Winer, MD, talks about how growing up with hemophilia helped him connect with patients Aug 02, 2022 podcast
Do Therapy-Related Hot Flashes in Breast Cancer Signal Worse Outcomes? Swedish study finds reduced DFS in women who used drugs for hot flashes Jun 22, 2022
Diabetes Threatens Long-Term Survival in Metastatic Breast Cancer 5-year survival rates were not affected, however Jun 13, 2022
A Better Way to Irradiate Lethal CNS Metastases? Randomized trial makes case for proton craniospinal irradiation for leptomeningeal spread Jun 08, 2022
Forego Radiotherapy for Women With Low-Risk Luminal A Breast Cancer? Study shows 5-year local recurrence rate of 2.3% with lumpectomy and endocrine therapy alone Jun 07, 2022
Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progression First randomized support for strategy in progressive metastatic HR+/HER2- breast cancer Jun 06, 2022
Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancer DESTINY-Breast04 extends agent's benefits to historically tough-to-treat disease Jun 05, 2022
Capivasertib-Fulvestrant Combo Ups Survival in ER+/HER2- Metastatic Breast Cancer But benefit seems to be predominantly in patients with PI3K/AKT/PTEN pathway alterations Jun 05, 2022
Sacituzumab Govitecan Boosts PFS in Late-Line HR+/HER2- Metastatic Breast Cancer "This may be something that really changes the lives of these women for the better," expert says Jun 05, 2022
Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer More than half of everolimus-treated patients permanently discontinued treatment Jun 02, 2022
Prone Beats Supine Positioning for WBRT in Women With Large Breasts Prone position led to lower rates of moist desquamation May 27, 2022
Black Patients Often Never Given a Chance to Join Breast Cancer Trials But survey finds several actionable findings that could boost enrollment May 26, 2022
Vaginal Estrogen 'Underutilized' in Women With GSM After Breast Cancer Prescribing rate is half that of women with no breast cancer history May 13, 2022
Novel Combo Falters in Metastatic Triple-Negative Breast Cancer No PFS benefit with addition of ceralasertib to olaparib May 05, 2022
Screening, Early Detection Remain Keys to Lower Cancer Mortality Presidential panel sets course to remove barriers, increase services, and improve uptake May 05, 2022
Antibody-Drug Conjugate Promising for Breast Cancer With Brain Mets High intracranial response rates with trastuzumab-deruxtecan observed in TUXEDO-1 trial May 04, 2022
Young Cancer Survivors Face Higher Risk of Death From Second Malignancies Study finds 25% higher risk of secondary cancers versus general public, 84% higher risk of death May 04, 2022
Menstrual Cycles Point to Link Between Sex Hormones and Long QT Research suggests new tools for risk stratification and therapy May 01, 2022
DCIS Recurrence Often Represents a New Primary Breast Cancer Almost a fifth of cases unrelated to primary DCIS, raising questions about current treatment Apr 11, 2022
RT Prior to Mastectomy, Reconstruction Shows Promise U.K. study demonstrates low complication rates and good aesthetic results Apr 08, 2022
Is Sentinel Node Biopsy Necessary for Older Breast Cancer Patients? Study finds positive lymph nodes not an indicator for chemotherapy Apr 07, 2022
New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
3D Mammograms Deliver Fewer False-Positive Findings However, half of women will have a false positive with annual screening with DBT Mar 25, 2022
Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
FDA OKs PARP Inhibitor as Adjuvant Therapy in Early Breast Cancer Olaparib (Lynparza) approved for high-risk patients with germline BRCA mutations Mar 14, 2022
Fluorescence-Guided Lumpectomy Shows Promise Imaging system reduced the need for re-excision in one-fifth of patients Mar 11, 2022
Androgen Receptor Agonist Active in Resistant ER+ Breast Cancer Also: Combination targets uncommon form of advanced HER2-mutant disease Mar 09, 2022
More Options for Precision Medicine in Metastatic Triple-Negative Breast Cancer Moving beyond chemotherapy to immunotherapy, PARP inhibitors, ADCs, combinations Mar 08, 2022
Chipping Away at the Dogma of Axillary Dissection in Breast Cancer Ongoing trials could help some women avoid even less-invasive sentinel lymph node biopsy Mar 07, 2022
Clinical Picture Brightens for HER2+ Breast Cancer With Brain Metastases New therapies breach blood-brain barrier to improve response, survival Mar 07, 2022
Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer Defining high risk, considering role of Ki-67, BRCA mutations Mar 05, 2022
Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiation Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
Highly Mutated Breast Cancer Responds to Immunotherapy Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
